Literature DB >> 8106603

Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses.

D S Park1, L A Selvey, S R Kelsall, I H Frazer.   

Abstract

Proteins derived from the E6, E7 and L1 ORFs of HPV16 and the E7 ORF of HPV18 were produced in insect cells using a baculovirus expression system. HPV ORFs were inserted into baculovirus transfer vectors pAcYM1 or pVL1393/2, and recombinant baculoviruses isolated using a combination of limiting dilution and plaque assay. Using HPV-specific antisera and monoclonal antibodies HPV proteins were identified in lysates of Spodoptera frugiperda (Sf-21) cells infected with HPV-recombinant baculovirus. Immunoreactive HPV16 E7 protein produced in Sf-21 cells had an apparent M(r) of 19 kDa, larger than that predicted from the amino acid sequence, and similar to that of native HPV16 E7 protein in HeLa and CaSki cells. The apparent M(r) of recombinant HPV18-E7, HPV16-L1 and HPV16-E6 proteins was equivalent to the M(r) values predicted from the amino acid sequence. Thermostability studies revealed that the half-life of HPV16-E7 protein in Sf-21 cell lysate was approx. 20 h at 4 degrees C, 2 h at 22 degrees C, and less than 30 min at 37 degrees C. HPV16 L1, HPV16 E7 and HPV18 E7 proteins were predominantly localised in the nucleus of recombinant baculovirus-infected Sf-21 cells, whereas recombinant HPV 16 E6 protein was localised in both the cytoplasm and nucleus of infected insect cells. Northern blot analysis of RNA derived from insect cells infected with vAc16E6E7, a recombinant baculovirus containing both HPV16 E6 and E7 ORF's, revealed the presence of only E6 ORF transcripts, suggesting that the splicing of RNA products derived from the E6 and E7 ORF's, as observed in cervical cancer-derived cell lines, is not performed in insect cells. Baculovirus-derived HPV proteins have similar biological properties to the native proteins and should be suitable for studies on the immunology of HPV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106603     DOI: 10.1016/0166-0934(93)90115-8

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16.

Authors:  G J Fernando; B Murray; J Zhou; I H Frazer
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.

Authors:  R P Viscidi; K L Kotloff; B Clayman; K Russ; S Shapiro; K V Shah
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

3.  Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein.

Authors:  S Iyengar; K V Shah; K L Kotloff; S J Ghim; R P Viscidi
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

4.  Trop2 gene: a novel target for cervical cancer treatment.

Authors:  Xiaoqi Liu; Siqi Li; Faping Yi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553

5.  Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model.

Authors:  Linda Petrone; Maria G Ammendolia; Armando Cesolini; Stefano Caimi; Fabiana Superti; Colomba Giorgi; Paola Di Bonito
Journal:  J Transl Med       Date:  2011-05-18       Impact factor: 5.531

6.  Antisense RNA directed to the human papillomavirus type 16 E7 mRNA from herpes simplex virus type 1 derived vectors is expressed in CaSki cells and downregulates E7 mRNA.

Authors:  Ilkka Kari; Stina Syrjänen; Bo Johansson; Piritta Peri; Bin He; Bernard Roizman; Veijo Hukkanen
Journal:  Virol J       Date:  2007-06-04       Impact factor: 4.099

7.  A vaccine to prevent cervical cancer: academic and industrial collaboration and a Lasker award.

Authors:  Edward M Scolnick
Journal:  Clin Transl Immunology       Date:  2017-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.